MAP3K5 and metabolic dysfunction-associated steatohepatitis: Compared to the ASK-1 inhibitor selonsertib38 and the FXR agonist ocaliva39, KY19334 showed higher effectiveness in improving the pathological features of the liver in HFD + CCl4-induced NASH mouse models when administered at identical concentrations.